Who Is Involved

Michael Weiner, MD, is a Professor in Residence in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer’s Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. After graduating from the Johns Hopkins University in 1961, he obtained his MD from SUNY Upstate Medical Center in Syracuse, New York in 1965, and he completed his internship and residency in Medicine from Mt. Sinai Hospital in 1967. From 1967-1968, Dr. Weiner completed a residency and clinical fellowship in Metabolism from Yale-New Haven Medical Center. In 1970, he completed a research fellowship in Nephrology from Yale University School of Medicine and a research fellowship in Biochemistry from the University of Wisconsin Institute for Enzyme Research in 1972, followed by a joint appointment in the Department of Medicine, Renal Section from the University of Wisconsin Institute in 1972. In 1974 he became an Assistant Professor of Medicine (Nephrology) at Stanford University, and in 1980 he became an Associate Professor of Medicine (Nephrology) at UCSF. In 1983, he established the Magnetic Resonance Unit at the San Francisco VA Medical Center, which became the Center for Imaging of Neurodegenerative Diseases in 2000. In 1990, he became a Professor of Radiology, Medicine, Psychiatry and Neurology at UCSF. Dr. Weiner’s research activities involve the development and utilization of MRI and PET for investigating and diagnosing neurodegenerative diseases. In 1980, Dr. Weiner was one of the first to perform MRS on an intact animal, and subsequently pursued his goal to develop MRI/S as a clinical tool. In 1988, his group used MRS to show that the amino acid N acetyl aspartate (NAA), a marker of healthy nerve cells, is reduced in the epileptic focus in the brain. In 2004, Dr. Weiner’s group reported that reduced NAA predicts development of Alzheimer’s disease in mildly impaired elderly subjects. During the past 25 years he has worked to develop and optimized the use of MRI, PET, and blood-based biomarker methods to diagnose Alzheimer’s disease and other neurodegenerative disorders. Also, Dr. Weiner’s research focuses on monitoring effects of treatment to slow progressions in Alzheimer’s disease, and detecting Alzheimer’s disease early in patients who are not demented, but risk subsequent development of dementia. He is the Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative, a 14-year national longitudinal study of over 1500 subjects which is aimed at validating biomarkers for Alzheimer’s disease at 60 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He also launched the BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on more than 60,000 participants. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer’s disease and other brain disorders. Recently he has focused on developing inexpensive, scalable, tools to identify normal elders at risk for cognitive decline and dementia, and to provide the Brain Health Registry software to facilitate the work of other investigators. Dr. Weiner has mentored over 120 postdoctoral fellows, has authored 821 peer reviewed research papers and 62 book chapters. He holds 19 separate research grants. He has received numerous honors including the Middleton Award for outstanding research in the Veterans Administration, the Nancy and Ronald Reagan Award for research from the Alzheimer’s Association, and the Potemkin Award for research in Picks Disease, Alzheimer’s disease, and other neurodegenerative disorders from the American Association of Neurology and the American Brain Foundation.

Dr. Mackin is Associate Professor in the Department of Psychiatry at the UCSF School of Medicine where he has served as Principal Investigator for six grants from the National Institutes of Health. His research work has focused on a wide range of neurodegenerative diseases including Alzheimer’s, dementia, late life depression, and traumatic brain injury. Dr. Mackin has spearheaded pioneering work in the assessment of cognitive functioning pre and post treatment, and has closely examined the neuropsychiatric symptoms of underlying neurodegenerative diseases with the aim of more fully understanding the range of symptoms that can arise from diseases like Alzheimer’s or dementia.

Juliet Fockler is a Program Director and Grant Manager for the Brain Health Registry. She manages all activities associated with specific BHR projects, including contact with investigators and sites, setting up contracts and monitoring budgets. She plans, evaluates and tracks tasks and deliverables to ensure milestones and goals are attained. Juliet also works as the Grant Manger for Dr. Weiner’s Alzheimer’s Disease Neuroimaging Initiative (ADNI) projects. Prior to CIND, Juliet worked at UCSF Clinical and Translational Science Institute where she served as the Program Coordinator for a campus-wide funding agency and award program.